表达区间及表达系统（Source）
Mouse monoclonal antibody is produced from a hybridoma resulting from fusion of SP2/0 myeloma and B-lymphocytes obtained from a mouse immunized with Bevacizumab F(ab')2.
亚型（Isotype）
IgG1/kappa
特异性（Specificity）
Recognizes Bevacizumab specifically, no cross reactivity with other humanized antibodies.
纯度（Purity）
>95% as determined by SDS-PAGE.
制剂（Formulation）
Lyophilized from 0.22 μm filtered solution in Tris with Glycine, Arginine and NaCl, pH7.5. Normally trehalose is added as protectant before lyophilization.
重构方法（Reconstitution）
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
存储（Storage）
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
- 4-8°C for 12 months in lyophilized state;
- -70°C for 3 years under sterile conditions after reconstitution.
电泳（SDS-PAGE）
Anti-Bevacizumab Antibodies (recommended for neutralizing assay) on SDS-PAGE under reducing (R) condition. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 95%.
活性（Bioactivity）-ELISA
Anti-Bevacizumab Antibodies bridging ELISA for Anti-Drug Antibody (ADA) assay development. Immobilized bevacizumab at 0.05 µg/mL, add increasing concentrations of Anti-Bevacizumab Antibodies (recommended for neutralizing assay) (Cat. No. BEB-Y12, 10% human serum) and then add biotinylated bevacizumab at 5 µg/mL. Detection was performed using HRP-conjugated streptavidin with a sensitivity of 62 ng/mL.
Protocol
Demonstration of the specificity of Anti-Bevacizumab Antibodies (recommended for neutralizing assay) (Cat. No. BEB-Y12) to the bevacizumab.
Protocol
Measured by its neutrlizing ability in a functional ELISA. Immobilized bevacizumab at 2 μg/mL (100 μL/well) can bind pre-mixed Anti-Bevacizumab Antibodies (recommended for neutralizing assay) (Cat. No. BEB-Y12) and Biotinylated Human VEGF 165 (Cat. No. VE5-H82Q0) with a inhibition rate of 96%.
Protocol
活性（Bioactivity）-SPR
Anti-Bevacizumab Antibodies (recommended for neutralizing assay) (mouse IgG1, Cat. No. BEB-Y12) captured on CM5 chip via anti-mouse antibodies surface, can bind human bevacizumab with an affinity constant of 0.08 nM.
Protocol
背景（Background）
A recombinant humanized monoclonal IgG1 antibody that binds to and inhibits the biologic activity of human vascular endothelial growth factor (VEGF). Bevacizumab contains human framework regions and the complementarity-determining regions of a murine antibody that binds to VEGF. Bevacizumab is produced in a Chinese Hamster Ovary mammalian cell expression system in a nutrient medium containing the antibiotic gentamicin and has a molecular weight of approximately 149 kilodaltons.
